Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has developed a new small-molecule oral compound for the treatment of Parkinson’s disease, FHND-1002, which demonstrated neuronal protection in models of neurodegenerative diseases and neuron trauma.
Proof-of-concept findings had shown that mRNA silencing of striatal Cav1.3 channels prevented and reversed established levodopa-induced dyskinesia in parkinsonian rats, with these effects being maintained in aged rats.
The generation of pathogenic autoantibodies is a crucial event in the development of inflammation and complement activation, leading to immune cell responses.
Vanishing white matter disease (VWM) is a rare and progressive leukoencephalopathy caused by loss-of-function mutations, in a recessive pattern of inheritance, in any of the genes encoding eIF2B, a guanine nucleotide exchange factor for eIF2 and an effector of the integrated stress response (ISR). At last week’s American Academy of Neurology meeting, Calico Life Sciences LLC and Abbvie Inc. presented preclinical results for their brain-penetrant compound ABBV-CLS-7262 (fosigotifator sodium tromethamine) in VWM.
The U.S. FDA’s green light April 17 for Abbvie Inc. to expand the label of Qulipta (atogepant) – the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine, with language that includes prevention of such headaches chronically in adults – provided a welcome addition to the arsenal, but sufferers are still waiting for an improved remedy. Vaxxinity Inc. just might have it. And with a vaccine, no less.
New and updated preclinical and clinical data presented by biopharma firms at the European Academy of Neurology Congress, including: Bristol Myers Squibb, Horizon, Teva.
New and updated preclinical and clinical data presented by biopharma firms at the American Academy of Neurology annual meeting, including: Clene, Emalex, Genentech, H. Lundbeck, Horizon, Mitsubishi, Neurelis, Neurocrine, Neuroderm, TG.
New and updated preclinical and clinical data presented by biopharma firms at the American Academy of Neurology Annual Meeting, including: Autobahn, Avadel, Lundbeck, Prothena, Teva.
RSS
